New subsidiary created as Company’s production arm for large scale Spider Silk production

ANN ARBOR, Mich., – April 24, 2018 –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces today that it has received approval for the establishment of its new Vietnamese subsidiary, Prodigy Textiles Co. Ltd.  The Company is happy to announce it has received, from Vietnam, its official investment registration certificate for the new subsidiary.  The establishment of the Company’s first subsidiary is seen by management as a major milestone toward its long term goal of establishing large scale spider silk production. 

Vietnam has been the focus of the Company’s efforts to launch commercial scale production of recombinant spider silk, due to the country’s existing silk production infrastructure.  The Company’s advanced silk production platform was designed specifically to fit within and utilize existing silk industry infrastructure.  The Company’s systems were designed that way in order to provide what its founder and CEO, Kim Thompson, believes to be a significant and nearly insurmountable competitive advantage.

While the establishment of Prodigy Textiles Co. Ltd. is viewed by the Company as a major milestone toward commercialization and large scale production, establishing production in Vietnam requires a separate government issued enterprise registration certificate. 

“What a great moment for Kraig Labs and the entire Spider Silk industry.  We anticipate that our new subsidiary in Vietnam will open the doors and pave the way for spider silk production and our commercialization efforts,” said Thompson.  “I want to thank our COO, Jon Rice, and our exceptional team of professional consultants who have worked tirelessly to make the founding of this production arm of our Company a reality.”

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

As the Company prepares for commercialization of its engineered spider silk, Kraig Labs shares information on the developing industry.

ANN ARBOR, Mich., –Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, releases the following statement regarding developments in the growing Spider Silk Industry.

Spider silk’s toughness is said to be 10 times greater than steel and some silks are nearly as elastic as rubber.  According to some studies, spider silks can be two to three times tougher than even Kevlar, which explains why so many researchers have targeted this fiber for protective clothing and body armor applications, as well as other potential military applications including technical undergarments and more practical ropes.

Numerous scientific studies have highlighted spider silk’s many intrinsic qualities and why it may be the ideal fiber for a slew of applications.  For example, spider silk’s maximal resilience, or ability to absorb energy, makes it one of the sturdiest materials on a weight-to-weight basis. These properties could make spider silk the foundation for many lightweight products, including air bags, seat belts, flexible bridge suspension cables, sports helmets and motor vehicle panels.

Additionally, studies have shown spider silk to be antimicrobial, biocompatible, hypoallergenic and totally biodegradable. Spider silk is a biomaterial that could be the platform on which to develop many medical technologies, like better bandages, elastic ligaments, and artificial tendons and even biodegradable water bottles.

Concurrent to Kraig Labs positioning for commercial production of its advanced fibers, many independent scientific studies have shown great promise in a vast array of potential spider silk applications.  The Company would like to congratulate all efforts that advance spider silk technologies.  A few recent examples of that work are provided below.  Each of these reports is entirely unaffiliated with Kraig Labs, and we therefore have not and cannot authenticate any specific conclusions. 

• Extremely thin sutures for eye or nerve surgery http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0016990
• Biosensors https://phys.org/news/2012-10-eco-friendly-optics-spider-silk-talents.html  
• Hearing aids https://www.healthyhearing.com/report/52826-Spider-silk-could-offer-breakthrough-in-hearing-aid-microphones
• Air quality improvement https://www.sciencedaily.com/releases/2014/01/140114113339.htm
• Artificial skin https://www.livescience.com/15443-artificial-skin-spun-spider-silk.html

As noted in the linked report, just the chronic wounds, such as bedsores in hospitalized patients, afflict 6.5 million in the United States for an estimated $25 billion annually. The Company believes that the various scientific discoveries in the spider silk space were instrumental in seeing over $300 million in funding flow into spider silk platform development over the past few years. One of the Company’s current competitors is approaching $196 million in aggregate funding, including $106 million in 2017, potentially valuing that pre-production technology at more than $1 billion dollars, when applying a commonly used valuation formula.

http://www.kblbinvestors.com/new-breakthroughs/

“As Kraig Labs prepares to transition into commercial production, we plan to expand our R&D focus and, given the tremendous interest in spider silk, we believe that we will have many great opportunities to grow newly discovered application into new business lines with strong growth potential. As we initiate a process to explore further scientific alliances our objective is to help maximize the future value of Kraig Labs,” stated Kim Thompson, Kraig Labs’ CEO and Founder. 

Industrial applications may include flexible bridge suspension cables, better fishing nets and unrippable paper. Spider silk’s well-balanced combination of strength and elasticity may even be combined with graphene to create the next generation of metamaterials.

Under funding from the US Army Research Office and the National Science Foundation professor Xinwei Wang at Iowa State University published a paper on Spider silks ability to conduct heat as well or better than most materials, including very good conductors such as silicon, aluminum and pure iron.  That discovery reportedly “opens a door for soft materials to be another option for thermal conductivity tuning,” as stated by professor Wang in the above reference publication.  This may inspire better semiconductors and lead to the creation of flexible, heat-dissipating parts for electronics, microchips, better clothes for hot weather, bandages that don’t trap heat and many other everyday applications.

By designing a high performance fiber, based on a proven efficient and ecologically friendly production platform, the Company’s objective is to target a broad cross section of applications in the $160 billion (projected) technical fibers market and the budding smart textile markets.  The Company intends to also target the mundane markets, like active wear and the $5 billion raw silk fibers market, which have tighter pricing elasticity.

 “It’s very exciting to think that we may be positioned to focus our efforts and resources on participating in advancing some of the many researchers who approach us to employ our fibers for various potential mechanical applications and we’re looking forward to collaborations that could open a new realm of possibilities for our technology,” said Jon Rice, Kraig Labs’ COO.

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,”

“foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

New larger Hybrid Cocoons provide production excitement

ANN ARBOR, Mich., –  April 11, 2018 – Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, announces follow up to its recently introduced new Hybrid Spider Silk Silkworm Cocoons, which were produced at the Company’s new research and development facility.

Development for the new hybrid was completed in-house, at Kraig Labs R&D facility using its Dragon Silk colony silkworms and a commercial mundane silkworm strain, which resulted in an estimated 100% increase in cocoon weight, compared to the cocoons that the Company was producing just four months ago in Indiana.

The Company understood that silkworms have been producing mundane silk for thousands of years and, that by employing the existing sericulture infrastructure, as well as expertise and traditions, it can cost effectively scale-up its transgenic spider silk silkworm production. According to Kraig Labs’ data, the Company should be able to commercialize some of the toughest natural fibers for almost the same cost as normal every day silk.

Eight countries produce the majority of world’s silk today, all of which have the resources and expertise to bring the Company’s fibers to market through mass production.  These countries have the potential to play a part in expanding Kraig Labs’ production footprint.

The Company believes that the new hybrid cocoons, along with its first recombinant spider silk producing silkworms and the development of Dragon Silk, are among the biggest sericulture breakthroughs in modern history.  As such, it’s important that the host countries respect Intellectual Property.  This is one of the reasons that Kraig Labs is looking at the potential of launching production in Vietnam.

“When I originally set out on the journey to mass produce spider silk, I knew that there were multiple production platform options.  Each of the obvious production platforms had serious shortcomings, including most importantly, an inability to produce spider silk at an acceptable price point.  I focused on inserting silkworms with the relevant gene sequence because silkworms have proven to be economically efficient and commercially viable natural silk producers.  In my opinion, silkworm remains the only economically viable platform,” stated Kim Thompson, Kraig Labs’ CEO and Founder.  “Kraig Labs’ R&D facility is a powerful tool to help us achieve optimum fiber and business performance,” Thompson concluded.

The activity in our industry has recently increased dramatically; most notably, multiple companies reportedly having raised over $300 million in combined funding to produce synthetic silks, which require chemicals and other steps to create their product. While these companies have interesting technological approaches, we believe, they lack the cost effectiveness of our silkworm based technology.  In our opinion, those approaches have no real way to commercialize spider silk in a way that takes advantage of the properties that make spider silk special, or at price points that are competitive with mundane silk.

 “Our production optimization initiatives are vital steps in the drive towards cost structure optimization and our new cocoons have shown us that even the most efficient fiber making process that exists in the world today, can be improved. A 100% increase in cocoon size from our existing products without any increased labor is a substantial win for our shareholders,” said Jon Rice, Kraig Labs’ COO.

We have posted our cost analysis on the existing market, and believe it confirms our ability to lead in this space, and why our excitement is growing to begin our first large scale production.  For further details concerning Kraig Labs’ cost advantages and comparative analysis, please go to www.kraiglabs.com/comparison

The Company is updating production plans and will update the shareholders and other interested parties when appropriate.

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter   

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.

The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,”

“foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – April 3, 2018- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the Company has successfully produced the first recombinant spider silk cocoons from the new line of hybrid transgenic silkworms recently created at its Michigan production and research facility.  This new hybrid line was created by combining one of the Company’s best performing recombinant spider silk lines with a commercial strain, resulting in the largest cocoons in the Company’s history. 

The first generation cocoons from this hybrid cross have exceeded the Company’s expectations with some cocoons nearly twice as large as the original spider silk line cocoons.  These larger cocoons reduce operating and handling costs throughout the production process and yield longer silk threads.  Mechanical performance testing of this new hybrid spider silk line is expected to begin shortly. 

“Crossing our recombinant spider silk silkworm lines with larger traditional silkworm lines is an element of both our research roadmap and commercialization plans.  The results we’ve seen from this first crossing confirm the benefits of those strategies,” said Jon Rice, COO.  “The size of these new hybrids is beyond what we expected in a first generation hybrid and we are very interested to see how performance testing results compare to the original silkworm lines.  We anticipate creating many additional hybrids, over the coming quarters, combining the performance of our spider silk lines with these larger commercial strains.  We expect these efforts will increase our production efficiency and lower our cost to produce recombinant spider silk.”

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

The Company identifies and implements plan to improve its recombinant spider silk

ANN ARBOR, Mich., – January 25, 2018- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the Company has recently implemented an expanded material performance testing procedure for its recombinant spider silk technology. This procedure is part of the Company’s efforts to continuously improve its operations and products. 

With this new expanded testing, the Company has already identified variances in material properties for its transgenic silkworm lines, which fall outside of the Company’s target ranges.  This variance is believed to be the result of genetic drift within the Company’s silkworm strains. 

In response to this new discovery, the Company has implemented an intensive selective breeding program to leverage the results of the newly established testing procedure.  The Company has also begun a cross breeding project to reinvigorate its transgenic lines with commercial silk genetics.  Combined, the expanded testing and selective breeding efforts are designed to allow the Company to more tightly control silk properties, while at the same time, creating the necessary genetic diversity within each line.  

The increased throughput and capacity for material testing, enabled by the Company’s new facilities and new testing protocol, is expected to identify even more opportunities for material and process improvements over the coming quarters.  The Company intends to use these discoveries to improve its operations and its products. 

“The expanded capacity for testing, which resulted from our decision to insource a major portion of our research operations, has already proven its significant value to the Company,” said Jon Rice, COO. “The results from performance testing, under the new testing protocol, have already been translated into an action plan.  The ability to quickly translate those results into an action plan is a great example of the value in consolidating our research and production into a single facility.  The efforts already underway to improve our testing and selective breeding should result in an improved process and more uniform final product.  Our plan is to improve quality back to our target range before spooling up for mass production.  This could cause a delay in commercialization if the other parts of our commercialization plan fall into place earlier. Uniform materials, improved quality control, and minimizing the performance variance will play an important part in our work to commercialize spider silk.  The information gained from this program will continue to inform our drive for continuous improvement.”

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter.

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (w), a fully reporting biotechnology company, is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – January 19, 2018- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the Company succeeded in creating a new hybrid transgenic silkworm at its Michigan production facility.  This is the first hybrid silkworm created at the new Michigan facility, which recently opened in October of 2017. 

This is the first new hybrid line developed in conjunction with the Company’s US Army contract and is the next step in its program to expand its commercial recombinant spider silk offerings.  The new recombinant spider silk strain combines properties from one of the Company’s best performing transgenics with a large commercial silkworm line, to produce larger cocoons and even stronger silk.

“Creating our first hybrid in the new facility is a great moment for the Company,” said Jon Rice, COO. “The transgenic line that we used, as the base for this new hybrid, has been under development for some time.  We are very eager to review the test results for this new line, as they come in.   The opportunity to soon analyze its capabilities, once transformed into a commercial line, are very exciting.”

To view the most recent edition of Kraig’s Spider Sense quarterly newsletter and/or to sign up for Company alerts, please go to www.KraigLabs.com/newsletter.

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (w), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

ANN ARBOR, Mich., – January 8, 2018- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the US ARMY has fully funded its ongoing contract to develop new recombinant spider silk fibers. The additional funding, just over $420,000, brings the total allocated funding on the contract to $1.02 million. This second phase of the Company’s contract with the US ARMY, valued at $921,000, began in July of 2017 and is focused exclusively on the development of new spider silk fibers. The Company is currently utilizing multiple approaches to create these transgenics, with performance that surpasses the original Dragon SilkTM that was produced for the baseline contract.

“The US ARMY’s choice to exercise the base contracts option period and to dramatically increase the total contract value gave us the ability to boost our research and development efforts substantially,” said Jon Rice, COO. “Under this expanded scope we are directed to develop new transgenics, with greater strength and toughness than anything we’ve ever seen before. With the allocation of the remaining contract funding, the US ARMY has now obligated all of the dollars committed in that contract award.”

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (w), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
(720) 288-8495
ir@KraigLabs.com

Dear Friends,

Merry Christmas, Happy Hanukkah and Seasons Greetings to all of our Shareholders!

Christmas is a season not only of rejoicing but of reflection. — Winston Churchill

As we look forward to the New Year, let us all take a moment to reflect upon the events of 2017…

2017 was a year full of major milestones and a series of firsts for Kraig Labs.  In our first quarter, Kraig saw advancements in nearly all aspects of our production operations.  We signed a land lease and planted 2,000 mulberry trees on our own mulberry plantation in Texas, strengthening our domestic production capability base.  We held a series of successful meetings and gained strong support from foreign government officials in our efforts to open international production operations, bringing us to the verge of an international production launch.  We produced and shipped the first production batch of Dragon Silk cocoons for processing under our contract with the US Army, proving that our technology can be quickly and efficiently scaled.  But this was just the beginning.

Through the balance of the year, we have continued to make major changes and advancements to the business.  In August, Kraig announced that the US army exercised their option to increase our contract for spider silk to more than $1.0 Million, nearly ten times the original contract value.  In September, we announced the termination of our long term equity line financing with Calm Seas Capital.  This move has freed the Company to grow and explore better financing options.

In October, we more than tripled the size of our domestic production operations, moving from our pilot location in Indiana to our new research and production headquarters in Michigan.  This move has for the first time brought our research and production teams under one roof, vastly improving our efficiency and economies of scale on every level.  That effort alone has already borne fruit in the cross-pollination of ideas and training among all our staff.  Not to mention, the move was seamless, and production at the new facility was up and fully running within less than 30 days!

In the last quarter, Kraig’s team built out a laboratory, for a fraction of the cost of a traditional lab build-out, with the capacity and capability to create new and exciting transgenics.  With Kraig’s move in the third quarter and the accompanying lab build-out at the new facility, the Company has moved most of its molecular biology from the university laboratory into our own facility with our own full time staffing.  We are already working to develop the next generation designs for stronger and tougher spider silk in our new in-house laboratory. 

With so many firsts and so many advancements from the fundamentals all the way through to a million dollar contract with the US Army, one cannot help but wonder why our market valuation has lagged.  Isn’t the Company stronger after the US Army executed its million dollar contract to deliver spider silk than it was before?  It is, and remains, the opinion of Company management that our valuation remains disjointed from the fundamental reality of the accelerating progress we’re seeing in our business every day.  In particular, we have seen dramatic positive changes in our internal fundamentals over the last two quarters. 

In addition to all of the progress we’ve made domestically in production, in R&D, and in our Army contract, we are also making significant progress establishing overseas production.  We believe that production at a location with existing silk infrastructure is key to unlocking substantial value for our shareholders, better aligning the Company valuation to the fundamentals of our business, and bringing our revolutionary materials to mass market.  We believe that given the foundation we have laid in 2017, it is merely a matter of time before we are able to launch that larger scale international production.  The holdup on that front is regulatory approval, the timing of which is not within the Company’s control.

It has been said many a time before, that the holidays are the most wonderful time of the year.  That sentiment is ringing truer than ever at Kraig Biocraft Laboratories.  We are proud of the significant strides Kraig Biocraft has made in improving our technological and competitive position this year.

As we review 2017 and how far we’ve come, we look forward towards building upon that foundation and making 2018 spectacular.  We thank you for your faith and continued support.  We believe that we have the most passionate shareholders, and that you are vital to our successful navigation of this emerging industry.

2017 was full of operational and business model improvements, even if those have not yet been reflected in our valuation.  The year has brought us many moments to celebrate, and we stand on the cusp of clearing a number of significant Company milestones, including the potential for international production volumes.

We see substantial opportunity in the various markets we are targeting.  We enter 2018 on a fundamentally solid footing, with great expectations for what the New Year holds for our technology.

It is in this spirit of the holidays that we extend our warmest greetings and best wishes for the New Year.  We accomplished much in the last year, but there is no doubt in our mind that our best days are in front of us. 

The Kraig Labs’ team kindly thanks you for your trust and continuing loyalty. We hope that you are surrounded by love, and warmth, this holiday season and that the holidays bring you many reasons to smile.

Kim K Thompson                                                                              Jon Rice

Founder and Chief Executive Officer                                                Chief Operations Officer

 About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information

Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could”, “spectacular”, “dramatic”, or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This letter does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com

New Laboratory to Develop Next Generation Spider Silk

ANN ARBOR, Mich., – December 14, 2017- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company”), the leading developer of spider silk based fibers, today announced that the Company has completed the build out of new laboratory space in its new research and production center.  The Company expects to begin the testing of existing spider silk formulations and the construction of new formulations before Christmas under its ongoing contract with the US Army to develop and deliver high performance spider silk polymers for protective applications. 

In just over two weeks the Company has staffed and equipped a fully functional laboratory and is now in the process of developing the next generation of spider silk products.  Consistent with the Company’s Ethos of efficiency and frugality, the lab was finished ahead of schedule, and under budget. 

“The opening of this new Lab is a watershed moment for the Company,” said Jon Rice, COO.  “Our new facility gives us the capacity to design, develop, and test new Spider Silk formulations, which give us the ability to rapidly develop new products going into 2018. We have brought on additional staff over the last 60 days, to take our ground breaking Spider Silk technology to the next level. Recent developments have reinvigorated our team, making us as excited today, as we were when we began our journey.”

About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.

Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.

Ben Hansel, Hansel Capital, LLC

(720) 288-8495

ir@KraigLabs.com